Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.
about
Patient reported outcome measures in neurogenic bladderClinical use of the β3 adrenoceptor agonist mirabegron in patients with overactive bladder syndromeDoes fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladderMinimum important difference for validated instruments in women with urge incontinence.Finding unrecognized information in overactive bladder clinical trial data: a new approach to understanding placebo and treatment effects.The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trialsCorrelation between overactive bladder symptom score and neuropsychological parameters in Alzheimer's disease patients with lower urinary tract symptom.Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale.Impact of transobturator tape treatment on overactive bladder symptoms, particularly nocturia, in patients with mixed urinary incontinence.Correlation between Metabolic Syndrome and Lower Urinary Tract Symptoms of Males and Females in the Aspect of Gender-Specific Medicine: A Single Institutional Study.The female urinary microbiome: a comparison of women with and without urgency urinary incontinence.Development of the Incontinence Utility Index: estimating population-based utilities associated with urinary problems from the Incontinence Quality of Life Questionnaire and Neurogenic Module[Chronic pollakiuria: cystectomy or psychotherapy].Functional MRI of the Brain in Women with Overactive Bladder: Brain Activation During Urinary Urgency.Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ERNGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndromeAcupuncture for adults with overactive bladder: a systematic review protocol.Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity.Correlation between psychological stress levels and the severity of overactive bladder symptomsLower urinary tract disease: what are we trying to treat and in whom?Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS).Incontinence medication response relates to the female urinary microbiota.Prevalence of overactive bladder and stress urinary incontinence in women who have sex with women: an internet-based surveyHypnotherapy for treatment of overactive bladder: a randomized controlled trial pilot studyPsychometric Properties of the Korean Version of the Overactive Bladder Questionnaire (OAB-q) in a Korean Population.The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB populationOveractive bladder in adults with sickle cell disease.Perceptions of "urgency" in women with interstitial cystitis/bladder pain syndrome or overactive bladder.Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptomsObjective Evaluation of Overactive Bladder: Which Surveys Should I Use?Does Instruction to Eliminate Coffee, Tea, Alcohol, Carbonated, and Artificially Sweetened Beverages Improve Lower Urinary Tract Symptoms?: A Prospective Trial.Assessment of Proportion of Hidden Patients Having Symptoms of Overactive Bladder and Why Has It Been Hidden in Female Outpatients Admitted to HospitalEfficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency.Use of the SF-36 quality of life scale to assess the effect of pelvic floor muscle exercise on aging males who received transurethral prostate surgery.Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy TreatmentImpact of childhood and recent traumatic events on the clinical presentation of overactive bladder.The validity and responsiveness of the ICECAP-A capability-well-being measure in women with irritative lower urinary tract symptoms.A phase II dose-ranging study of mirabegron in patients with overactive bladderCorrelations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo.
P2860
Q26767322-6ACE4850-1A9D-4962-A4B5-E964D21F1C9EQ26783536-9208E11E-0BD5-4E36-9E9A-9EEB8EB19D3EQ27000698-598C9FAB-60F4-4C6C-8D10-4B9384E57045Q27497430-AF03C561-905B-458C-8368-5FC7DE41A036Q30353491-82A30FEF-537F-48D1-AF0E-CABE6A4832C9Q30570112-52078691-3F33-4293-8123-939CA3143ECDQ30894093-DF4DA588-5C30-42ED-B42B-E9BE3C4357DBQ33692634-6511678E-73E1-4954-8B66-E6988A7D1D87Q34035456-1D310727-AE79-4F2A-B6BB-2F24BAE975ADQ34037962-7C079003-5F32-4946-BA9C-BB08CB223D10Q34139222-360CCC0E-19B3-4F0D-A799-79659CAB1BE3Q34165475-FBD809EC-1410-4B6A-81AD-F3E70B55C1CFQ34334025-2DCBAE40-DCFA-470E-BFBC-029D07C35A51Q34438162-3DCC93E2-DF76-46E8-BEE4-6026A17A7D7FQ34636180-45EB054D-CE5B-464E-96D7-D858329B5C4EQ34693256-330BA20C-7320-45FC-A5C0-7750334AACB1Q34774149-F073D4D2-DE78-4FBF-A9BC-368F21793DF8Q34903525-75472721-478B-4490-9BCF-4F69E0B4A032Q35141099-6BED46BF-713A-47D6-8D11-F41BAA090FF8Q35170051-02F06D64-D53E-45CB-890B-6B22884EBFC8Q35545715-0CBB6DC3-3CE8-4EB8-B9B2-C56FCC9903ADQ35780487-213C631C-8305-4CFD-966E-0253EDF77AE1Q35794040-28BCFDFB-849B-4168-B652-5F3D96991093Q35899973-76901BA5-747F-4FBC-9255-5D411C5B8813Q36074232-0D1B8C10-8C3E-4EC6-8B5E-1D1CB3B1660BQ36092237-C63FB545-2D38-4ADD-8AB3-28305357DBBFQ36157230-47495368-7093-47C3-A46B-41D9E274666DQ36161766-351442B4-0652-4AE7-8902-CC7F684872BFQ36441757-07F13EE5-140D-40A5-BBF0-9154AC6915F1Q36487166-0BB801BB-BA70-4B03-BB9D-69659A219551Q36630704-4A372723-2D98-4B1E-BCCE-9B9184578AC8Q36705814-6E5792DB-988D-45B5-984D-472BA1C5A129Q36760524-71E44A4F-6D4D-4646-8D30-4EB394853633Q36919948-B4134222-3A1D-4675-95BE-915B23AB7719Q36922163-6445BF90-8B0E-4435-84FC-BB0322C1BAE8Q37034036-44A0E027-3231-47A2-8892-C80931EEA45DQ37088666-06232AFF-371A-430D-906B-63C1A6663995Q37096149-486AD45A-F60C-420D-9003-BA090B969F63Q37100337-282E981C-BBD9-4DD1-A5E5-1439CD721387Q37114121-788AED01-45D0-4E7E-BAB1-9ECBC1A3BB14
P2860
Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Psychometric validation of an ...... life questionnaire: the OAB-q.
@en
Psychometric validation of an ...... life questionnaire: the OAB-q.
@nl
type
label
Psychometric validation of an ...... life questionnaire: the OAB-q.
@en
Psychometric validation of an ...... life questionnaire: the OAB-q.
@nl
prefLabel
Psychometric validation of an ...... life questionnaire: the OAB-q.
@en
Psychometric validation of an ...... life questionnaire: the OAB-q.
@nl
P2093
P356
P1476
Psychometric validation of an ...... life questionnaire: the OAB-q.
@en
P2093
J Bentkover
P2888
P304
P356
10.1023/A:1016370925601
P577
2002-09-01T00:00:00Z
P5875
P6179
1031960373